03:58:30 Europe / Stockholm

Prenumeration

2022-11-11 08:25:00

Redeye embraces the strong gross margin of 84% vs REe of 80% in the quarter, and we judge the slight deviation in sales and OPEX compared to our estimates as relatively insignificant. We embrace the company’s efforts in setting up its organization for a future US launch through its CLIA lab and reiterate our SEK120 base case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/